StreetInsider.com News Articles

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Wed, 23 Apr 2025 08:00:00 -0500

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocol
Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ulcers (DFU)
Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing
The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer

SYDNEY, April 10, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), a leading developer of a new class of synthetic anti-infectives, today announced a capital raising of up to approximately A$15.8 million (before costs) (Capital Raising) consisting of:

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Thu, 10 Apr 2025 08:00:00 -0500

A$5.0 million commitment received from Australian-based private investor
A$10.8 million Entitlement Offer at the same offer price as the placement
Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026
Directors intend to take up entitlements in part or in full in the Entitlement Offer